Stay updated on Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.

Latest updates to the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page footer now displays Revision: v3.5.4, replacing the previous v3.5.3, indicating a new build of the page.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedThe page’s footer version/release label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a site software update without changing the clinical trial information displayed.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check77 days agoChange DetectedThe site revision tag was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check85 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check113 days agoChange DetectedPrimary peritoneal carcinoma was added to the listed conditions and a new Resources entry for the Genetic and Rare Diseases Information Center was included; the revision notes indicate a version update from v3.4.1 to v3.4.2.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Bevacizumab+Cyclophosphamide in Recurrent Ovarian Ca Clinical Trial page.